AstraZeneca Loses US Patent on Asthma Drug –

AstraZeneca Loses US Patent on Asthma Drug
Apotex and Actavis had received approval from the US Food and Drugs Administration (FDA), but they are yet to launch generic versions of the medicine, which is used to control and prevent asthma symptoms in children aged between 12 months to 8 years.
US court blow for AstraZeneca on asthma drugEvening Standard
AstraZeneca to contest US court ruling over asthma medicineIFA Magazine
AstraZeneca loses US drug patent judgmentFinancial Times
Bloomberg –GlobalPost
all 17 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.